Senolytic dosage: mouse arithmetic and a handful of patients

Why senolytic dosing is intermittent

The rationale is genuinely elegant. Senescent cells accumulate slowly and do not divide, so if you kill them you do not need to keep killing them. A short burst of dosing followed by a long gap should, in principle, clear the population and let months pass before it rebuilds.^[1]

That logic gave the field its hit-and-run design, and it was carried directly into the human pilots and into every consumer protocol since. It remains a rationale rather than a finding: nobody has compared intermittent against continuous dosing in people.

What the human trials actually dosed

Limited evidence The best-known human senolytic study gave dasatinib with quercetin to patients with idiopathic pulmonary fibrosis over a few days and reported improvements in physical function measures.^[2] A related study in diabetic kidney disease used the same combination and reported reduced senescent cell burden in tissue.^[3]

Both enrolled around a dozen patients. Both used dasatinib, a prescription tyrosine kinase inhibitor with real toxicity, doing much of the pharmacological work. Later reviews of senolytic clinical development describe a field still at the pilot stage.^[4]

So the human dosing evidence is: a drug you cannot buy, given to sick patients, for a few days, measured against markers.

Where the fisetin senolytic dosage came from

Not from any of that. Fisetin protocols trace to the 2018 screen identifying it as the most potent senolytic among ten flavonoids, with intermittent dosing in progeroid and aged mice.^[5] Convert the rodent dose by body weight and you arrive at the large intermittent amounts circulating online.

Two problems sit inside that conversion. Body-weight scaling between mice and humans is an assumption rather than a rule, and fisetin absorbs poorly, so an equivalent milligram figure does not imply an equivalent tissue concentration. Meanwhile the Interventions Testing Program, which retests promising compounds across independent sites, did not find a lifespan extension with fisetin.^[6]

You'd have to eat 15 pounds of strawberries in five minutes to get the kind of dose we're giving.

The measurement problem

Senescent cell burden is measured by analyzing tissue. That is why the human trials took biopsies, and it is why nothing available to a consumer can tell you whether a protocol did anything at all.

The consequence for dosing is decisive. Without a marker there is no titration, no way to know when a repeat cycle is warranted, and no way to distinguish a working protocol from an inert one. Every schedule in circulation is therefore a guess with a calendar attached.

Why more is not obviously better

Selectivity is the entire point of a senolytic: killing senescent cells while sparing healthy ones. That selectivity is a property of a specific concentration range, not a guarantee of the molecule.

Pushing the dose up in pursuit of a stronger effect risks losing the selectivity that made the class interesting, and with poorly characterized compounds there is no way to know where that line sits. Quercetin's own evidence summary describes limited bioavailability and modest effects at ordinary doses.^[7]

What a defensible position looks like

Recognize which parts are real. The senolytic concept is well supported by genetic experiments in mice. The human trials are real, small, and used a prescription drug. The supplement protocols are extrapolations.

I give it maybe a 50-50 chance. We're doing the trials because we don't know if they're going to work.

If you take flavonoid senolytics anyway, the honest framing is a low-risk bet on an unvalidated schedule, not the execution of a protocol. Our review of the senolytic evidence covers the class, and the fisetin page covers the compound with the most enthusiasm and the failed retest.

What would establish a real senolytic dosage

A trial comparing doses against a measured reduction in senescent cell burden, followed by a trial showing that the reduction improves a clinical outcome. Neither exists for any compound available without a prescription.

Until they do, senolytic dosage is a topic where confident numbers signal confidence rather than knowledge. Our supplement evidence review applies the same standard across the category.

Frequently asked questions

What is the standard senolytic dosage?

There is no standard. The human trials that exist used dasatinib with quercetin on intermittent schedules in tiny patient groups. Fisetin protocols circulating online are extrapolated from a mouse study, and no dose has been validated against a human outcome.

Why is senolytic dosing intermittent?

Because the hypothesis is that clearing senescent cells is an occasional event rather than a continuous process. Kill the cells, then stop, since the cells take time to reaccumulate. It is a coherent rationale and it has never been tested against continuous dosing in people.

What is the hit-and-run protocol?

Two or three consecutive days of dosing, then weeks or months off. The pattern comes from the animal literature and from the design of the small human pilots, and the specific intervals in circulation are conventions rather than findings.

What doses were used in human trials?

The pilot studies used dasatinib, a prescription cancer drug, together with quercetin over a few days. They enrolled a handful of patients each and measured senescent cell markers or short-term physical function, not health outcomes.

Where do the fisetin doses online come from?

From scaling the mouse study. The doses used in that work, converted by body weight, produce the large intermittent amounts circulating in protocols. That conversion assumes a translation nobody has validated for this compound.

Is a higher senolytic dose more effective?

Unknown, and the assumption is risky. Selectivity is what makes a senolytic useful: killing senescent cells and not healthy ones. Higher doses of a poorly characterized compound are as likely to lose that selectivity as to increase the effect.

How often should a senolytic be taken?

Protocols suggest monthly or quarterly cycles with no evidence deciding between them. Since there is no accessible test of senescent cell burden, there is also no way to know when or whether a repeat is warranted.

Can you tell if a senolytic worked?

Not outside a research setting. Measuring senescent cell burden requires tissue analysis, which is why the human trials that did it took biopsies. Nothing available to a consumer measures it.

Are senolytics safe at these doses?

The pilot trials reported acceptable short-term tolerability in patients. Dasatinib is a prescription drug with real toxicity. Fisetin and quercetin appear well tolerated at supplement doses, and the high intermittent amounts in protocols have not been studied for long-term safety in healthy people.

Should healthy people take senolytics at all?

Every human trial so far has enrolled patients with a disease, which is the appropriate place to test something new. Extending an unvalidated protocol to healthy people is exactly the leap the trials have not made.

Does taking it with fat help?

Both fisetin and quercetin absorb poorly and are fat-soluble, so pairing with a meal containing fat is the usual advice. It is plausible pharmacokinetics and it does not resolve whether achievable concentrations do anything.

Is quercetin needed alongside fisetin?

No combination has been tested. The pairing people copy is dasatinib with quercetin, where the prescription drug is doing much of the work. Substituting fisetin for dasatinib produces a different protocol with no trial behind it.

What monitoring makes sense?

Nothing specific is established, since none of this is a validated therapy. Anyone taking a prescription senolytic is doing so under a clinician who will define monitoring. Anyone self-dosing flavonoids has no marker to follow.

What is the honest summary on senolytic dosage?

The class is one of the better ideas in aging biology and the dosing is entirely unsettled. Every protocol in circulation is a translation from mice or a copy of a tiny patient pilot, and the compound with the most enthusiasm behind it failed its lifespan retest.